Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States

INTRODUCTION: This study assessed the cost-effectiveness of ozanimod compared with commonly used disease-modifying therapies (DMTs) for relapsing–remitting multiple sclerosis (RRMS). METHODS: Annualized relapse rate (ARR) and safety data were obtained from a network meta-analysis (NMA) of clinical t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kantor, Daniel, Pham, Timothy, Patterson-Lomba, Oscar, Swallow, Elyse, Dua, Akanksha, Gupte-Singh, Komal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195930/
https://www.ncbi.nlm.nih.gov/pubmed/37000386
http://dx.doi.org/10.1007/s40120-023-00463-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195930/
https://www.ncbi.nlm.nih.gov/pubmed/37000386
http://dx.doi.org/10.1007/s40120-023-00463-y

Ejemplares similares